AIMT - Aimmune Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.08
+0.02 (+0.09%)
As of 2:58PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close23.06
Open23.08
Bid23.30 x 900
Ask23.34 x 800
Day's Range22.36 - 23.62
52 Week Range21.47 - 42.00
Volume254,963
Avg. Volume627,614
Market Cap1.43B
Beta (3Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)-3.53
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.60
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 12, 2018. Aimmune’s senior management will discuss AR101’s clinical profile in peanut-allergic patients and the company’s preparations for a potential 2019 U.S. commercial launch. The event will also bring together leading expert allergists to discuss the emerging treatment landscape in peanut allergy, including the recent New England Journal of Medicine1 publication of the landmark PALISADE trial of AR101, the largest and only successful phase 3 peanut allergy immunotherapy trial to date.

  • Benzinga10 days ago

    The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 29) Allakos Inc (NASDAQ: ALLK ) Emergent Biosolutions Inc ...

  • Business Wire12 days ago

    Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science. The sale of shares was made pursuant to the terms of the Securities Purchase Agreement entered into on November 11, 2018, by Aimmune and Nestlé Health Science, as previously reported by Aimmune. Additional details regarding the equity investment and strategic collaboration agreement can be found in Aimmune’s Form 8-K filed with the Securities and Exchange Commission on November 13, 2018.

  • GlobeNewswire12 days ago

    Market Trends Toward New Normal in Genomic Health, Beacon Roofing Supply, Cronos Group, Aimmune Therapeutics, OGE Energy, and Spartan Motors — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
    American City Business Journals14 days ago

    Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics

    Why a South Bay company thinks it can disrupt a tough antibiotics market — and more in our weekly Health Care Digest.

  • Biotech Slides As Investors Digest Results Of Peanut-Allergy Test
    Investor's Business Daily21 days ago

    Biotech Slides As Investors Digest Results Of Peanut-Allergy Test

    Aimmune Therapeutics fell as investors digested a study testing its oral immunotherapy in children with life-threatening peanut allergies. Aimmune stock lost more than 7% by midday.

  • Peanut Allergy Remedy Offers Both Hope and Risk
    Bloomberg21 days ago

    Peanut Allergy Remedy Offers Both Hope and Risk

    The key takeaway: After a year of  treatment, two-thirds of children who took the medication were able to eat small amounts of peanuts. This isn’t a cure. But it has a shot at U.S. government approval, and could make the lives of children with few options easier and safer. Instead, Aimmune has taken a pre-existing method of allergy protection — carefully exposing children to de-fatted peanut flour to desensitize them — and finely tuned it in an effort to pass muster with the Food and Drug Administration. Aimmune produces capsules or sachets with a precise quantity of its drug, which is then mixed into food. The study showed that this can be highly effective for many children. Being able to eat a peanut or two may not permit a change in diet, but the treatment offers protection against potentially deadly accidental exposure and a path toward a less regimented and fearful lifestyle. That’s no small achievement, given that peanut allergies have become increasingly common in America.

  • The Wall Street Journal22 days ago

    [$$] Experimental Drug Shows Promise Protecting Against Peanut Allergies

    An experimental drug derived from peanuts protected some children and adolescents with life-threatening peanut allergies, according to a study, allowing the subjects to eat small amounts of peanuts without suffering a serious reaction. The drug, from a small California company, Aimmune Therapeutics, didn’t work for everyone, has some side effects and hasn’t been approved by regulators for sale. Peanut allergies have emerged as a life-threatening peril for many parents, forcing them to pore over ingredients for any signs of peanuts and to equip their children—and their children’s schools—with devices to help with sudden and unexpected allergic reactions.

  • Business Wire22 days ago

    Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the New England Journal of Medicine (NEJM) has published the full results of the landmark phase 3 PALISADE clinical trial of AR101, Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. PALISADE is the largest and first successful phase 3 peanut allergy immunotherapy trial to date. “This publication in the New England Journal of Medicine recognizes the rigor, scale and importance of the PALISADE trial, which will inform ongoing research in food allergy and could change practice for peanut allergy,” said A. Wesley Burks, M.D., Executive Dean and Curnen Distinguished Professor of Pediatrics, University of North Carolina School of Medicine, member of the Aimmune Scientific Advisory Board, and senior author of the NEJM publication.

  • Are Options Traders Betting on a Big Move in Aimmune Therapeutics (AIMT) Stock?
    Zacks26 days ago

    Are Options Traders Betting on a Big Move in Aimmune Therapeutics (AIMT) Stock?

    Investors need to pay close attention to Aimmune Therapeutics (AIMT) stock based on the movements in the options market lately.

  • Reuters28 days ago

    Nestle raises stake in food allergy drug developer Aimmune

    The deal raises Nestle's stake to about 19 percent from 14.5 percent as of Feb. 26 and its total investment in Aimmune to $273 million. The companies also extended their two-year strategic pact to develop therapies for food allergies by another two years, Aimmune said on Monday. In the United States, there is no approved treatment for peanut allergies, a medical condition that is becoming increasingly common and could be fatal.

  • Business Wire28 days ago

    Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $98 million, increasing Nestlé Health Science’s ownership of Aimmune to approximately 19 percent.

  • Associated Presslast month

    Aimmune Therapeutics: 3Q Earnings Snapshot

    The Brisbane, California-based company said it had a loss of 89 cents per share. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...

  • Business Wirelast month

    Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights

    BRISBANE, Calif.-- -- Recently completed Phase 3 RAMSES study confirms safety profile of AR101 in peanut-allergic children and teens BLA submission for AR101 on track for December 2018 Management to host analyst event on Wednesday, December 12 th , in New York Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial ...

  • Business Wirelast month

    Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting

    — Oral Presentation on Data from Aimmune’s Pivotal Phase 3 PALISADE Trial —

  • Business Wirelast month

    Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors, effective October 31, 2018. Dr. Haumann’s extensive biotech and pharmaceutical leadership experience includes more than 20 years of development and discovery work in allergy and pulmonary medicines. “I’m excited to welcome Brett to the Aimmune Board,” said Jayson Dallas, M.D., President and CEO of Aimmune.

  • Business Wirelast month

    Aimmune Therapeutics to Participate in Upcoming Investor Conferences

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy, and dupilumab is Regeneron and Sanofi’s fully human monoclonal antibody that inhibits signaling of IL-4 and IL-13 cytokines, which are believed to be major drivers of type 2 inflammation.

  • Business Wire2 months ago

    Aimmune Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 3

    Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that President and CEO Jayson Dallas, M.D., will participate in a fireside chat at the Cantor Global Healthcare Conference in New York on Wednesday, October 3, 2018, at 10:55 a.m. Eastern Time. A live webcast of the fireside chat will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies.

  • Business Wire3 months ago

    Aimmune Therapeutics to Present at Three Investor Conferences in September

    BRISBANE, Calif.-- -- Wells Fargo Healthcare Conference, September 5 Baird Global Healthcare Conference, September 6 Bank of America Merrill Lynch Global Healthcare Conference, September 12 Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will present at three investor conferences in ...

  • Associated Press4 months ago

    Aimmune Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had a loss of 91 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Business Wire4 months ago

    Aimmune Therapeutics Announces Second Quarter 2018 Financial Results

    Aimmune Therapeutics, Inc. , a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2018.